Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 0.1 %

NYSE OGEN opened at $0.28 on Thursday. The company has a 50-day moving average price of $0.33 and a two-hundred day moving average price of $0.59. Oragenics has a 52 week low of $0.25 and a 52 week high of $5.14. The stock has a market cap of $3.47 million, a price-to-earnings ratio of -0.04 and a beta of 0.40.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.